Eli Lilly shares jump after FDA approves weight loss pill Foundayo, boosting its obesity franchise and rivalry with Novo Nordisk, with aggressive pricing expected to drive uptake
Eli Lilly shares jump after FDA approves weight loss pill Foundayo, boosting its obesity franchise and rivalry with Novo Nordisk, with aggressive pricing expected to drive uptake